Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in patients with neovascular age-related macular degeneration (nAMD). Enzeevu ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of servicePeter Stenico ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback